To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC72862 | Formamide Featured |
Formamide (Methanamide; Formimidic acid) is a clear liquid amide derived from formic acid. It allows for the denaturation and renaturation of nucleic acids at room temperature. Formamide-induced DNA denaturation when combined with detection of denatured DNA with a monoclonal antibody (MAb) makes it possible to specifically identify the apoptotic cells.
More description
|
|
| DC31324 | TRC102 Featured |
Methoxyamine is an orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
More description
|
|
| DC32883 | Levobunolol Hydrochloride Featured |
Levobunolol Hydrochloride is a non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity.
More description
|
|
| DC24043 | USP8-IN-22e Featured |
A potent, selective ubiquitin-specific protease USP8 inhibitor with IC50 of 0.28 uM.
More description
|
|
| DC42616 | EMBL Featured |
Novel inhibitor of MuRF1, attenuating skeletal muscle atrophy and dysfunction in cardiac cachexia
More description
|
|
| DC43413 | MRT-10 Featured |
MRT-10 is a seven-transmembrane receptor smoothened (Smo) antagonist with an IC50 of 0.65 μM in the micromolar range in various Hedgehog (Hh) assays. MRT-10 binds to the Smo receptor at the level of the Bodipycyclopamine binding site. MRT-10 can be used for the research of cancer[1][2].
More description
|
|
| DC21668 | ALLO-2 Featured |
ALLO-2 is a potent small molecule Smoothened (Smo) antagonist that inhibits Smo agonist Hh-Ag1.5-induced luciferase expression in TM3-Gli-Luc cells with IC50 of 6 nM.
More description
|
|
| DC36480 | JNK-IN-7 Featured |
JNK-IN-7 is a relatively selective JNKs inhibitor(IC50= 1.54/1.99/0.75 for JNK1/2/3); also bound to IRAK1, PIK3C3, PIP5K3 and PIP4K2C.
More description
|
|
| DC71608 | Euquinine Featured |
Euquinine is generally used as a febrifuge, antimalarial, and tonic.
More description
|
|
| DC31596 | ICI 156834 Featured |
Cefotetan Sodium, also known as ICI-156834 and YM-09330, is a second-generation cephalosporin, cephamycin antibiotic that is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative bacteria. Cefotetan binds to penicillin-binding proteins and disrupts the cell wall synthesis.
More description
|
|
| DC21182 | JNJ-53718678 Featured |
JNJ-53718678 (JNJ53718678, JNJ-678) is a potent (Kd=7.4 nM), small-molecule inhibitor of the F-glycoprotein-mediated complex membrane fusion process of the RSV.
More description
|
|
| DC22783 | PF-06446846 Featured |
PF-06446846 (PF-6446846) is a potent, highly selective inhibitor of PCSK9 translation with IC50 of 0.3 uM for inhibition the secretion of PCSK9 by Huh7 cells.
More description
|
|
| DC34053 | SM-7368 Featured |
SM-7368 inhibits TNF-alpha-induced MMP-9 upregulation in a concentration-dependent manner. SM-7368 strongly inhibits the TNF-alpha-induced invasion of HT1080 human fibrosarcoma cell line.
More description
|
|
| DC72487 | KCC-07 Featured |
KCC-07 is a potent, selective and brain-penetrant inhibitor of MBD2 (methyl-CpG-binding domain protein 2) with anticancer activity. It prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling.
More description
|
|
| DC70339 | dBRD9 dihydrochloride Featured |
dBRD9 dihydrochloride is a potent and selective degrader (PROTAC) of BRD9 with IC50 of 56.6 nM in MOLM-13 cells.dBRD9 is composed of the BRD9 inhibitor BI 7273 conjugated to the cereblon E3 ligase ligand pomalidomide.dBRD9 does not degrade BRD4 or BRD7 at concentrations up to 5 uM.dBRD9 exhibits antiproliferative effects in human AML cell lines.
More description
|
|
| DC72822 | MS023 hydrochloride Featured |
MS023 hydrochloride is a potent, selective and cell-active inhibitor of human type I protein arginine methyltransferases (PRMT), with IC50 values of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively.
More description
|
|
| DC47467 | UZH2 Featured |
UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM.
More description
|
|
| DC22378 | DPH Featured |
A cell-permeable, small-molecule c-Abl kinase activator with pEC50 of 6.1(EC50=794 nM).
More description
|
|
| DC7786 | ELN 441958 Featured |
ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.IC50 value: 0.26 nM (Ki)Target: B1 Receptorin vitro: ELN-441958 is a novel small molecule bradykinin B1 receptor antagonist, based on the inhibition of agonist-induced increases in intracellular calcium in native and recombinant cells. ELN-441958 does not inhibit the activation of the human bradykinin B2 receptor at concentrations up to 10 μM, showing that it is highly selective for B1 over B2 receptors. ELN-441958 also displays good selectivity for B1 over other receptors examined in a broad screening panel. It is >500-fold and >2000-fold selective for the B1 receptor over the human μ- and δ-opioid receptor, the most potent off-target activity identified. In IMR-90 cells expressing the native human B1 receptor, ELN-441958 produced a concentration-dependent antagonism of the DAKD-induced calcium mobilization with a KB of 0.12 nM. [1]in vivo: ELN-441958 is essentially completely absorbed and produces high plasma levels after oral administration in rhesus monkeys.ELN-441958 has a moderate clearance and volume of distribution in both species following i.v. administration, consistent with the high metabolic stability in rat, rhesus, and human microsomes. ELN-441958 has high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. The oral availability of ELN441958 in rats was 57%. ELN-441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED50 3 mg/kg s.c. [1]
More description
|
|
| DC32519 | SMAD3 Featured |
SMAD3 is a receptor-regulated intracellular protein that functions downstream of TGF-β and activin receptors and mediates their signaling, playing a role in cell proliferation, differentiation, apoptosis and formation of extracellular matrix. Smad3 Inhibitor, SIS3 is a cell-permeable pyrrolopyridine compound that selectively inhibits TGF-β1-dependent Smad3 phosphorylation and Smad3-mediated cellular signaling with no effect on Smad2, p38 MAPK, ERK, or PI 3-K signaling. It has been shown to reduce TGF-β1-induced type 1 procollagen expression and myofibroblast differentiation in normal dermal fibroblasts as well as scleroderma fibroblasts.
More description
|
|
| DC72066 | 5-Ethynyluridine Featured |
5-Ethynyluridine (5-EU) is a potent cell-permeable nucleoside can be used to label newly synthesized RNA. 5-Ethynyluridine can be used for isolation and sequencing of nascent RNA from neuronal populations in vivo. 5-Ethynyluridine can be used to identify changes in transcription in vivo in nervous system disease models.
More description
|
|
| DC72824 | TH1760 |
TH1760 is a first-in-class, potent, selective and cell-active NUDT15 (MTH2) inhibitor with an IC50 value of 25 nM.
More description
|
|
| DC21703 | STAT5 inhibitor 17f Featured |
A novel potent, selective inhibitor of phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation.
More description
|
|
| DC21702 | SC-99 Featured |
A novel selective STAT3 inhibitor that inhibits JAK2-STAT3 activation but has no effects on other transcription factors such as NF-κB, and kinases such as AKT, ERK, and c-Src.
More description
|
|
| DCY-109 | Linolenic acid Featured |
α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer[1].
More description
|
|
| DC20036 | PI3K/mTOR Inhibitor-2 Featured |
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity.
More description
|
|
| DC22498 | A-443654 Featured |
A potent and selective Akt inhibitor with Ki of 0.16 nM for Akt1.
More description
|
|
| DC20183 | UPGL00004 Featured |
UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
More description
|
|
| DC10395 | S107 Featured |
S107 is a RyR-selective 1,4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.
More description
|
|
| DC26020 | BAY2335218(BAY-218) Featured |
BAY2335218(BAY-218) is the first-in-class AhR antagonist for overcoming tumor-mediated immunosuppression.
More description
|
|